Floatz logo

Ampreloxetine

Symptomatic Neurogenic Orthostatic Hypotension

Theravance BiopharmaSmall moleculePhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Symptomatic Neurogenic Orthostatic Hypotension cohort.

Asset / SponsorPhaseRating
Droxidopa
William Ondo, MD
Phase 4BBB
Fipamezole
Juvantia Pharma Ltd
Phase 2CCC
Midodrine
Vanderbilt University Medical Center
Early Phase 1CC

Same molecule, other indications

Ampreloxetine is also rated in:

multiple system atrophyDormant
CCC
Indicative ·
51 / 100
View asset →
pure autonomic failureDormant
CCC
Indicative ·
51 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →